These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1625897)

  • 1. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
    Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
    Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
    Wyndaele JJ; de Meyer JM; de Sy WA; Claessens H
    Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.
    Armstrong DK; Convery A; Dinsmore WW
    Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of impotence with papaverine and phentolamine intracavernosal injection.
    Dinsmore WW
    Ulster Med J; 1990 Oct; 59(2):174-6. PubMed ID: 2278115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracavernous infusion of drugs].
    Bellorofonte C; Dell'Acqua S; Ruoppolo M; Zaatar C; Tombolini P
    Arch Ital Urol Nefrol Androl; 1992 Sep; 64(3):251-4. PubMed ID: 1439852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous papaverine for impotence in spinal cord injured patients.
    Kapoor VK; Chahal AS; Jyoti SP; Mundkur YJ; Kotwal SV; Mehta VK
    Paraplegia; 1993 Oct; 31(10):675-7. PubMed ID: 8259331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.
    Lin JS; Chang WC; Lui SM
    Proc Natl Sci Counc Repub China B; 1994 Jan; 18(1):12-6. PubMed ID: 8029369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Endocavernous drug infusions revisited].
    Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.